Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $38.82 million versus the consensus estimate of $44.5 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.